DE60219614D1 - 3, 7 thiaprostansäurederivate als mittel zur verminderung des augeninnendruckes - Google Patents

3, 7 thiaprostansäurederivate als mittel zur verminderung des augeninnendruckes

Info

Publication number
DE60219614D1
DE60219614D1 DE60219614T DE60219614T DE60219614D1 DE 60219614 D1 DE60219614 D1 DE 60219614D1 DE 60219614 T DE60219614 T DE 60219614T DE 60219614 T DE60219614 T DE 60219614T DE 60219614 D1 DE60219614 D1 DE 60219614D1
Authority
DE
Germany
Prior art keywords
thiaprostansäurederivate
augeninnendruckes
reduction
glaucoma
ocular hypertension
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60219614T
Other languages
English (en)
Other versions
DE60219614T2 (de
Inventor
Robert M Burk
Mark Holoboski
Mari F Posner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of DE60219614D1 publication Critical patent/DE60219614D1/de
Application granted granted Critical
Publication of DE60219614T2 publication Critical patent/DE60219614T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
    • C07C405/0033—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Paper (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Window Of Vehicle (AREA)
DE60219614T 2001-05-08 2002-05-06 3, 7 thiaprostansäurederivate als mittel zur verminderung des augeninnendruckes Expired - Lifetime DE60219614T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US851296 2001-05-08
US09/851,296 US6410591B1 (en) 2001-05-08 2001-05-08 3,7 or 3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure
PCT/US2002/014331 WO2002089813A2 (en) 2001-05-08 2002-05-06 3, 7 or 3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure

Publications (2)

Publication Number Publication Date
DE60219614D1 true DE60219614D1 (de) 2007-05-31
DE60219614T2 DE60219614T2 (de) 2007-12-27

Family

ID=25310439

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60219614T Expired - Lifetime DE60219614T2 (de) 2001-05-08 2002-05-06 3, 7 thiaprostansäurederivate als mittel zur verminderung des augeninnendruckes

Country Status (9)

Country Link
US (1) US6410591B1 (de)
EP (1) EP1385526B1 (de)
JP (1) JP2004529166A (de)
AT (1) ATE359794T1 (de)
AU (1) AU2002305416B2 (de)
CA (1) CA2446386C (de)
DE (1) DE60219614T2 (de)
ES (1) ES2284872T3 (de)
WO (1) WO2002089813A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410591B1 (en) * 2001-05-08 2002-06-25 Allergan Sales, Inc. 3,7 or 3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure
US7872045B2 (en) * 2001-06-14 2011-01-18 Allergan, Inc. Combination therapy for glaucoma treatment
US20050222094A1 (en) * 2001-06-14 2005-10-06 Burk Robert M Treatment of inflammatory bowel disease
US20030027853A1 (en) 2001-06-14 2003-02-06 Allergan Sales, Inc. 3, 7or3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure
RU2336081C2 (ru) * 2003-02-11 2008-10-20 Аллерган, Инк. Производные 10,10-диалкилпростановой кислоты для снижения внутриглазного давления
US7179820B2 (en) * 2003-06-06 2007-02-20 Allergan, Inc. Piperidinyl prostaglandin E analogs
US7186744B2 (en) * 2003-11-13 2007-03-06 Allergan, Inc. Prostamides for the treatment of glaucoma and related diseases
WO2006041875A1 (en) 2004-10-06 2006-04-20 Allergan, Inc. Novel prostamides for the treatment of glaucoma and related diseases
US7183324B2 (en) * 2004-11-23 2007-02-27 Allergan, Inc. 2,3,4-substituted cyclopentanones as therapeutic agents
US7893107B2 (en) * 2005-11-30 2011-02-22 Allergan, Inc. Therapeutic methods using prostaglandin EP4 agonist components
US20070232660A1 (en) * 2006-04-04 2007-10-04 Allergan, Inc. Therapeutic and delivery methods of prostaglandin ep4 agonists
US8183286B2 (en) * 2006-11-16 2012-05-22 Gemmus Pharma Inc. EP2 and EP4 agonists as agents for the treatment of influenza a viral infection
US8455547B2 (en) * 2008-02-05 2013-06-04 Allergan, Inc. Substituted cyclopentanes having prostaglandin activity
US7732443B2 (en) * 2008-03-18 2010-06-08 Yariv Donde Therapeutic substituted cyclopentanes
US7960378B2 (en) * 2008-03-18 2011-06-14 Allergan, Inc. Therapeutic compounds
RU2500674C2 (ru) * 2008-05-09 2013-12-10 Аллерган, Инк. Терапевтические соединения
EP2149552A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma AG 5,6 substituierte Benzamid-Derivate als Modulatoren des EP2-Rezeptors
EP2149554A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma Aktiengesellschaft Indolylamide als Modulatoren des EP2-Rezeptors
EP2149551A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma AG N-(Indol-3-ylalkyl)-(hetero)arylamidderivate als Modulatoren des EP2-Rezeptors
US20110293549A1 (en) 2009-02-03 2011-12-01 Athena Cosmetics, Inc. Composition, method and kit for enhancing hair
US8859616B2 (en) 2011-01-21 2014-10-14 Allergan, Inc. Compounds and methods for enhancing hair growth

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4937265A (en) * 1987-05-28 1990-06-26 Teijin Limited Antidiabetic method comprising 7-thiaprostaglandin E1 or its derivatives
JP3579448B2 (ja) * 1993-12-29 2004-10-20 大正製薬株式会社 プロスタグランジン誘導体、その塩およびその使用
JPH09286775A (ja) * 1996-04-24 1997-11-04 Taisho Pharmaceut Co Ltd プロスタグランジン誘導体
JPH10259179A (ja) * 1996-09-19 1998-09-29 Santen Pharmaceut Co Ltd 多置換アリールオキシ基を有するプロスタグランジン類およびその用途
JPH10265454A (ja) 1997-01-27 1998-10-06 Ono Pharmaceut Co Ltd ３，７−ジチアプロスタン酸誘導体、それらの製造方法およびそれらを有効成分として含有する薬剤
NO317155B1 (no) * 1997-02-04 2004-08-30 Ono Pharmaceutical Co <omega>-cykloalkyl-prostagladin-E<N>2</N>-derivater
US6043275A (en) 1998-04-16 2000-03-28 Ono Pharmaceutical Co., Ltd. 3,7-dithiaprostanoic acid derivative
AU2183900A (en) * 1998-12-24 2000-07-31 Alcon Laboratories, Inc. Ep4 receptor agonists for treatment of dry eye
US6545045B1 (en) * 1998-12-24 2003-04-08 Alcon Manufacturing, Ltd. Prostaglandin E agonists for treatment of glaucoma
JP2001151749A (ja) * 1999-11-24 2001-06-05 Taisho Pharmaceut Co Ltd プロスタグランジン誘導体
US6410591B1 (en) * 2001-05-08 2002-06-25 Allergan Sales, Inc. 3,7 or 3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure
CA2466757A1 (en) * 2001-12-03 2003-06-12 Merck & Co., Inc. Method for treating ocular hypertension

Also Published As

Publication number Publication date
EP1385526B1 (de) 2007-04-18
CA2446386A1 (en) 2002-11-14
CA2446386C (en) 2011-02-01
WO2002089813A2 (en) 2002-11-14
AU2002305416B2 (en) 2008-01-10
JP2004529166A (ja) 2004-09-24
DE60219614T2 (de) 2007-12-27
EP1385526A2 (de) 2004-02-04
ATE359794T1 (de) 2007-05-15
US6410591B1 (en) 2002-06-25
ES2284872T3 (es) 2007-11-16
WO2002089813A3 (en) 2003-02-27

Similar Documents

Publication Publication Date Title
DE60219614D1 (de) 3, 7 thiaprostansäurederivate als mittel zur verminderung des augeninnendruckes
CY1110322T1 (el) Αναστολεις της her3 δραστικοτητας
BR0310047A (pt) Análogos de 8-azaprostaglandina como agentes para diminuição de pressão intra-ocular
EA200201247A1 (ru) Соединения для лечения болезни альцгеймера
BRPI0006634B8 (pt) composição tópica compreendendo extrato de matricária no tratamento e prevenção de distúrbios inflamatórios
HK1069851A1 (en) Bone morphogenic proteins (bmp), bmp receptors andbmp binding proteins and their use in the diagnosis and treatment of glaucoma
DE60234919D1 (de) 3, 7 oder 3 und 7 thia- oder oxaprostansäure derivate als mittel zur senkung des augeninnendrucks
NO20030845D0 (no) Utvalgte fusjonerte pyrrolokarbazoler
BR9813767A (pt) Processo e composição para tratar glaucoma de glc1a
DE60101265D1 (de) Behandlung von augenschmerzen
ATE448785T1 (de) Behandlung von entzündlicher darmerkrankung
DE69940951D1 (de) Nd wachstumshemmende mittel
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
BR0017157A (pt) Derivados de 6-hidroxi-indazol para o tratamento de glaucoma
WO2001091796A8 (en) Methods, compounds and compositions for treating gout
EA200601238A1 (ru) Медикаменты для профилактики и лечения бромидроза и для улучшения запаха тела
BR0314459A (pt) Método para baixar e controlar a pressão intra-ocular e/ou para o tratamento de mamìferos sofrendo a partir de glaucoma e composto
ATE369856T1 (de) Verfahren zur behandlung von glaukom
NO20032411D0 (no) Anvendelse av substituerte 6-dimetylaminometyl-1-fenyl- cykloheksan-forbindelser for behandling av urininkontinens
EA200600115A1 (ru) Производные 2-аминобензойной кислоты
DE602004031225D1 (de) 3-oxa-8-azaprostaglandinanaloga als mittel zum senken des augeninnendrucks
DE69620573T2 (de) Mittel zur verminderung des augeninnendrucks
SE0100873D0 (sv) Method of treatment
FR2835253B1 (fr) Composes, en particulier de derives urees ou esters de l&#39;acide haloacetamidobenzoique et leur utilisation pour le traitement de maladies parasitaires
ATE350034T1 (de) Verwendung von epothilone zur behandlung hyperparathyreoidismus

Legal Events

Date Code Title Description
8364 No opposition during term of opposition